Press Release

January 13, 2021
1 min read

Notal Vision initiates study investigating at-home OCT monitoring of AMD


Press Release

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Notal Vision has initiated a longitudinal study to evaluate the ability of patients with wet age-related macular degeneration to perform daily self-imaging of their eyes using the Notal Home OCT device, according to a press release.

The investigational home-based OCT platform is designed to support patient management of wet AMD through patient-initiated retinal OCT scans, the release said.

“Remote OCT monitoring of wet AMD patients has the potential to personalize anti-VEGF treatment and improve outcomes while minimizing treatment burden by reducing the number of office visits,” Jeffrey S. Heier, MD, one of the study’s principal investigators and co-president and medical director of Ophthalmic Consultants of Boston, said in the release.

The study will remotely monitor 15 patients with wet AMD who are receiving standard of care anti-VEGF therapy for 90 days to track the presence of retinal fluid. Data will be automatically transmitted, and then the AI-based Notal OCT Analyzer will analyze and quantify intraretinal and subretinal fluid, the release said.

Data from a previous clinic-based trial showed image quality is sufficient for human graders to identify fluid in one of three consecutive tests, with a sensitivity of 97% and a specificity of 95%.

The technology received breakthrough device designation from the FDA in 2018, and the FDA clearance process is ongoing.